Equities

Evaxion Biotech A/S

EVAX:NAQ

Evaxion Biotech A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.15
  • Today's Change0.03 / 0.96%
  • Shares traded280.00
  • 1 Year change-34.38%
  • Beta-0.2559
Data delayed at least 15 minutes, as of Sep 19 2024 20:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5.581332
Total Receivables, Net1.071.091.34
Total Inventory------
Prepaid expenses1.702.490.64
Other current assets, total00.220.56
Total current assets8.351735
Property, plant & equipment, net4.344.685.17
Goodwill, net------
Intangibles, net--00.09
Long term investments------
Note receivable - long term0.030.210
Other long term assets0.170.160.19
Total assets132240
LIABILITIES
Accounts payable2.692.092.85
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.490.440.44
Other current liabilities, total3.911.241.04
Total current liabilities7.083.764.32
Total long term debt109.823.25
Total debt11103.69
Deferred income tax------
Minority interest------
Other liabilities, total0.150.140.15
Total liabilities18147.73
SHAREHOLDERS EQUITY
Common stock5.903.893.76
Additional paid-in capital------
Retained earnings (accumulated deficit)(11)4.4229
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity(4.73)8.3032
Total liabilities & shareholders' equity132240
Total common shares outstanding382423
Treasury shares - common primary issue------
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.